Abstract:Epithelial growth factor (EGF) and basic fibroblast growth factor (bFGF), and their receptors, epithelial growth factor receptor (EGFR) and bFGF receptor (bFGFR), are frequently overexpressed in high-grade gliomas. In the present study, the EGF and bFGF levels in U251 glioblastoma cell culture supernatants were determined by ELISA, and enhanced green fluorescent protein (EGFP)-labeled recombinant lentiviral expression vectors with small interfering RNA targeting the EGFR and bFGFR genes were constructed. The mRNA expression levels of EGFR, bFGFR, cluster of differentiation (CD)133, glial fibrillary acidic protein (GFAP), tubulin-β3 (TUBB3) and myelin basic protein (MBP) were determined using quantitative polymerase chain reactions in U251 cells prior to and following silencing of the EGFR and/or bFGFR genes. Prior to silencing, the U251 cells secreted EGF and bFGF, and expressed EGFR, bFGFR, CD133, GFAP, TUBB3 and MBP mRNA. Subsequent to silencing the EGFR and/or bFGFR gene, CD133 mRNA expression decreased and GFAP and TUBB3 mRNA expression increased. Silencing the EGFR and FGFR genes acted synergistically to downregulate CD133 expression. The downregulation of CD133 mRNA expression and the upregulation of GFAP and TUBB3 mRNA expression were not significantly different when blocking the EGFR and FGFR pathways. These results indicate that autocrine or paracrine EGF and/or FGF mechanisms exist in U251 cells. Knocking down the EGFR and/or FGFR genes downregulates CD133 mRNA expression and facilitates glial and neuronal differentiation in U251 cells.

Supplementary Figures and Tables from Epidermal Growth Factor Receptor and PTEN Modulate Tissue Factor Expression in Glioblastoma Through JunD/Activator Protein-1 Transcriptional Activity

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Expression of Dedifferentiation Markers and Multilineage Markers in U251 Glioblastoma Cells with Silenced EGFR and FGFR Genes.

Supplementary Figures 1-4 from Glioblastoma Proto-oncogene <i>sec61γ</i> is Required for Tumor Cell Survival and Response to Endoplasmic Reticulum Stress

Supplementary Figures 1-6, Tables 1-15, Methods from Epigenetic Silencing Mediated Through Activated PI3K/AKT Signaling in Breast Cancer

Supplementary Table 1 from RAGE Expression in Tumor-Associated Macrophages Promotes Angiogenesis in Glioma

Supplementary Figures and Tables from an IL6–Adenosine Positive Feedback Loop Between CD73<sup>+</sup> Γδtregs and CAFs Promotes Tumor Progression in Human Breast Cancer

SUPPLEMENTARY figure 6 from IGFBP2 Activates the NF-κB Pathway to Drive Epithelial–Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma

Supplementary Table 1, Figures 1-9 from Overexpression of Platelet-Derived Growth Factor-BB Increases Tumor Pericyte Content via Stromal-Derived Factor-1α/CXCR4 Axis

Supplementary Figure 2 from Fibroblast Growth Factor Receptor Mediates Fibroblast-Dependent Growth in EMMPRIN-Depleted Head and Neck Cancer Tumor Cells

Supplementary Figure 5 from Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal Transition

Supplemental Tables from Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer

Supplementary Figure 1 from Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal Transition

Supplementary Figure 4 from Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal Transition

Supplementary Figures &Tables from Reprogramming Transcription Factors Oct4 and Sox2 Induce a BRD-Dependent Immunosuppressive Transcriptome in GBM-Propagating Cells

Supplementary Tables from in Vivo Visualization and Characterization of Epithelial–Mesenchymal Transition in Breast Tumors

Supplementary Figure 2 from Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal Transition

Supplementary Figure 3 from Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal Transition

Supplementary Figures 1-4 from Angiocrine Factors Modulate Tumor Proliferation and Motility through EphA2 Repression of Slit2 Tumor Suppressor Function in Endothelium

Supplementary Figure Legends 1-9 from Overexpression of Platelet-Derived Growth Factor-BB Increases Tumor Pericyte Content Via Stromal-Derived Factor-1α/CXCR4 Axis